182 related articles for article (PubMed ID: 37635247)
1. Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma.
Yang C; You J; Pan Q; Tang Y; Cai L; Huang Y; Gu J; Wang Y; Yang X; Du Y; Ouyang D; Chen H; Zhong H; Li Y; Yang J; Han Y; Sun F; Chen Y; Wang Q; Weng D; Liu Z; Xiang T; Xia J
BMC Med; 2023 Aug; 21(1):327. PubMed ID: 37635247
[TBL] [Abstract][Full Text] [Related]
2. Nonviral mcDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma.
Wang H; Wang X; Ye X; Ju Y; Cao N; Wang S; Cai J
BMC Cancer; 2022 Jul; 22(1):814. PubMed ID: 35879685
[TBL] [Abstract][Full Text] [Related]
3. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X
Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119
[TBL] [Abstract][Full Text] [Related]
4. CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo.
Chicaybam L; Abdo L; Carneiro M; Peixoto B; Viegas M; de Sousa P; Fornazin MC; Spago MC; Albertoni Laranjeira AB; de Campos-Lima PO; Nowill A; Barros LRC; Bonamino MH
Hum Gene Ther; 2019 Apr; 30(4):511-522. PubMed ID: 30793967
[TBL] [Abstract][Full Text] [Related]
5. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial.
Dai H; Tong C; Shi D; Chen M; Guo Y; Chen D; Han X; Wang H; Wang Y; Shen P
Oncoimmunology; 2020 Nov; 9(1):1846926. PubMed ID: 33312759
[TBL] [Abstract][Full Text] [Related]
7. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo.
Rafiq S; Yeku OO; Jackson HJ; Purdon TJ; van Leeuwen DG; Drakes DJ; Song M; Miele MM; Li Z; Wang P; Yan S; Xiang J; Ma X; Seshan VE; Hendrickson RC; Liu C; Brentjens RJ
Nat Biotechnol; 2018 Oct; 36(9):847-856. PubMed ID: 30102295
[TBL] [Abstract][Full Text] [Related]
8. 4-1BB-Based CAR T Cells Effectively Reverse Exhaustion and Enhance the Anti-Tumor Immune Response through Autocrine PD-L1 scFv Antibody.
Cheng K; Feng X; Chai Z; Wang Z; Liu Z; Yan Z; Wang Y; Zhang S
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835603
[TBL] [Abstract][Full Text] [Related]
9. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
10. Minicircles for CAR T Cell Production by Sleeping Beauty Transposition: A Technological Overview.
Prommersberger S; Monjezi R; Shankar R; Schmeer M; Hudecek M; Ivics Z; Schleef M
Methods Mol Biol; 2022; 2521():25-39. PubMed ID: 35732991
[TBL] [Abstract][Full Text] [Related]
11. Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.
Yuti P; Sawasdee N; Natungnuy K; Rujirachaivej P; Luangwattananun P; Sujjitjoon J; Yenchitsomanus PT
Biomed Pharmacother; 2023 Dec; 168():115691. PubMed ID: 37844355
[TBL] [Abstract][Full Text] [Related]
12. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
13. Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells.
Sun B; Yang D; Dai H; Liu X; Jia R; Cui X; Li W; Cai C; Xu J; Zhao X
Cancer Immunol Res; 2019 Nov; 7(11):1813-1823. PubMed ID: 31484657
[TBL] [Abstract][Full Text] [Related]
14. Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma.
Wu X; Luo H; Shi B; Di S; Sun R; Su J; Liu Y; Li H; Jiang H; Li Z
Mol Ther; 2019 Aug; 27(8):1483-1494. PubMed ID: 31078430
[TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
16. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice.
Li D; Li N; Zhang YF; Fu H; Feng M; Schneider D; Su L; Wu X; Zhou J; Mackay S; Kramer J; Duan Z; Yang H; Kolluri A; Hummer AM; Torres MB; Zhu H; Hall MD; Luo X; Chen J; Wang Q; Abate-Daga D; Dropulic B; Hewitt SM; Orentas RJ; Greten TF; Ho M
Gastroenterology; 2020 Jun; 158(8):2250-2265.e20. PubMed ID: 32060001
[TBL] [Abstract][Full Text] [Related]
17. Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors.
Monjezi R; Miskey C; Gogishvili T; Schleef M; Schmeer M; Einsele H; Ivics Z; Hudecek M
Leukemia; 2017 Jan; 31(1):186-194. PubMed ID: 27491640
[TBL] [Abstract][Full Text] [Related]
18. Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report.
Sun H; Xing C; Jiang S; Yu K; Dai S; Kong H; Jin Y; Shan Y; Yang W; Wang Z; Xiao J; Wang H; Wang W; Li Z; Shi K
Front Immunol; 2022; 13():963031. PubMed ID: 36059488
[TBL] [Abstract][Full Text] [Related]
19. Targeting Lin28 axis enhances glypican-3-CAR T cell efficacy against hepatic tumor initiating cell population.
Patra T; Cunningham DM; Meyer K; Toth K; Ray RB; Heczey A; Ray R
Mol Ther; 2023 Mar; 31(3):715-728. PubMed ID: 36609146
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy.
Zhang Y; Wang P; Wang T; Fang Y; Ding Y; Qian Q
J Transl Med; 2021 Feb; 19(1):82. PubMed ID: 33602263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
